Arificial tear solution

A technology for artificial tears and uses, applied in the field of artificial tears, can solve the problems of not outstanding film-forming performance, impossible to achieve uniform distribution and wetting of the cornea, discomfort for extraocular treatment of eye diseases, etc., to achieve high retention capacity and reduce friction Effect

Inactive Publication Date: 2005-06-01
BAUSCH & LOMB INC
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For this reason, the substance is not suitable for use in the extraocular treatment of eye diseases, since it does not have outstanding film-forming properties, so it is not possible to achieve an even distribution and wetting of the cornea

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Make 0.1g Fluowet (trade name, Firma Clariant) OTL, 0.9g water and 99g perfluorophenanthrene (its surface tension σ=19mN / m;) Homogenize, sterilize at 121 ℃ for 15 minutes, then by means of a syringe on the mirror surface Coating and dispensing where the surface is wetted with an even, tear-free film.

Embodiment 2

[0033] According to a known method, by tetraethylpiperazinium salt of perfluorooctanoic acid (σ=15.9mN / m; 0.1g), a balanced amount of salt solution (BSS, 0.9g) and perfluorophenanthrene (σ=19mN / m; 99g) or perfluoroalkyl alcohol-ethoxylate (σ=19mN / m; 0.1g), BSS (0.9g) and perfluorophenanthrene (σ=19mN / m; 99g) to prepare Polyaphron gel and in autoclave Sterilize at 121°C for 15 minutes. This gel-like formulation was filled into a syringe and studied in the Draize experiment. In the Draize experiment, no inflammation was found. No adverse effects on tear secretion, eyelid and glandular mucus production or secretion in rabbits were found 2 weeks after application of the gel. Daily treatment was continued for about 16 more weeks without signs of incompatibility.

Embodiment 3

[0035] The formulation prepared according to Example 2 was administered in the eyes of rabbits. This is followed by rapid administration of known therapeutic agents for dilating the pupil. It is emphasized here that the action of the agent for dilating the pupil is lost as soon as the film of the artificial tear according to the invention is formed on the cornea. This serves as evidence for the ability of the formulations of the invention to form a thin, intact film on the cornea, like natural tears. Furthermore, this example shows that the formulations of the invention, once formed into a thin film on the cornea, prevent aqueous or water-soluble substances from coming into contact with the ocular surface, thereby producing a protective effect.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molar massaaaaaaaaaa
surface tensionaaaaaaaaaa
refractive indexaaaaaaaaaa
Login to view more

Abstract

A tear replacement solution that contains at least one water-soluble fluorosurfactant, water and a non-polar component, preferably in gel form, and a method for the external treatment for the eye of an mammal by applying the tear replacement solution to the eye, preferably by placing in the conjunctival sac.

Description

technical field [0001] The present invention relates to an artificial tear (tear substitute liquid) for external treatment of eyes. Background technique [0002] Artificial tears are used in the treatment of eye diseases such as frequently occurring keratoconjunctivitis sicca (so-called dry eye). Dry eye can have various causes. Common causes are in the elderly, rheumatic or medical Diseases (e.g. polyarthritis, diabetes and thyroid disease), diseases of antibodies to endogenous substances (Morbus Sjgren, lupus erythematosus, scleroderma), skin diseases, hormonal changes, nerve paralysis ( such as post-stroke, abnormal eyelids, tear gland removal), taking certain medications (such as beta-inhibitors, Anti-baby-Pile, sleeping pills, and sedatives), malnutrition, climate effects (ie, hot, dry Ambient air, season, air conditioner), environmental pollution (ozone, dust, solvent fumes, etc.), X-ray fluoroscopy, and long-term use of vasoconstrictive eye ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/107A61P27/04A61K9/06A61K9/00A61K31/02A61K31/03A61K31/08A61K31/16A61K31/18A61K31/185A61K31/19A61K31/215A61K31/495A61K31/695A61K31/755A61K31/80A61K47/12A61K47/14A61K47/20A61K47/24
CPCA61K9/0026A61K9/0048A61K31/02A61K31/03A61K31/08A61K31/16A61K31/18A61K31/185A61K31/19A61K31/215A61K31/495A61K31/661A61K31/695A61P27/04
Inventor D-H·曼兹J·德雷斯普M·温特
Owner BAUSCH & LOMB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap